• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed

    2/16/21 4:02:05 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $TLRY alert in real time by email
    SC 13D/A 1 d119834dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 4)*

     

     

    Tilray, Inc.

    (Name of Issuer)

    Class 2 Common Stock

    (Title of Class of Securities)

    88688T 100

    (CUSIP Number)

    Brendan Kennedy

    2701 Eastlake Ave. E., 3rd Floor

    Seattle, WA 98102

    Telephone: (206) 395-7505

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    February 16, 2021

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 88688T 100

     

      1. 

     

    Name of Reporting Persons.

     

    Brendan Kennedy

      2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐         (b)  ☐

     

      3.

     

    SEC USE ONLY

     

      4.

     

    Source of Funds (See Instructions)

     

    AF

      5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

      6.

     

    Citizenship or Place of Organization

     

    United States Citizen

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

      

      7.

      

    Sole Voting Power

     

    12,782,843 shares(1)

      

      8.

      

    Shared Voting Power

     

    0 shares

      

      9.

      

    Sole Dispositive Power

     

    12,782,843 shares (1)

      

    10.

      

    Shared Dispositive Power

     

    0 shares

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    12,782,843 shares (1)

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ☐

    13.

     

    Percent of Class Represented by Amount in Row (11)

     

    7.9% (2)

    14.

     

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)

    Consists of (1) 9,866,975 shares of Class 2 Common Stock held directly by Mr. Kennedy, (2) 2,634,053 shares of Class 2 Common Stock that are issuable upon the exercise of options held directly by Mr. Kennedy that are exercisable within 60 days of February 12, 2021, and (3) 234,940 shares of Class 2 Common Stock held directly by a limited liability company, of which Mr. Kennedy is the sole member and has sole voting and investment power decisions as it relates to such limited liability company.

     

    (2)

    Based on (1) 158,256,763 shares of Class 2 Common Stock that were outstanding as of December 15, 2020, set forth in the Issuer’s Current Report on Form 8-K filed with the SEC on December 21, 2020, (2) 2,634,053 shares of Class 2 Common Stock that are issuable upon the exercise of options held directly by Mr. Kennedy that are exercisable within 60 days of February 12, 2021, and (3) 46,875 shares of Class 2 Common Stock that are issuable upon the vesting of restricted stock units held directly by Mr. Kennedy that will vest within 60 days of December 15,

     

    2


    CUSIP No. 88688T 100

     

    Item 1.

    Security and Issuer.

    This Amendment No. 4 (“Amendment No. 4”) to Schedule 13D amends the statement on Schedule 13D filed on December 23, 2019 (the “Original Schedule 13D”), as amended by Amendment No. 1 as filed with the Securities and Exchange Commission on June 19, 2020 (“Amendment 1”), Amendment No. 2 as filed with the Securities and Exchange Commission on September 24, 2020, and Amendment No. 3 as filed with the Securities and Exchange Commission on October 16, 2020 (“Amendment 3” and together with the Original Scheduled 13D, Amendment No. 1, Amendment No. 2 and this Amendment No. 4, the “Schedule 13D”) with respect to the Class 2 Common Stock of Tilray, Inc. (the “Issuer”), having its principal executive office at 1100 Maughan Road, Nanaimo, BC, Canada. Except as otherwise specified in this Amendment No. 4, all items in the Schedule 13D, as amended by Amendment 1, Amendment 2, and Amendment No. 3, are unchanged. All capitalized terms used in this Amendment No. 4 and not otherwise defined herein have the meanings ascribed to such terms in the Original Schedule 13D.

    The Reporting Person is filing this Amendment No. 4 to report a decrease in the percentage of the class beneficially owned by the Reporting Person due to an increase in the aggregate number of outstanding securities of the Issuer.

     

    Item 5.

    Interest in Securities of the Issuer

     

      (a)

    State the aggregate number and percentage of the class of securities identified pursuant to Item 1 (which may be based on the number of securities outstanding as contained in the most recently available filing with the Commission by the issuer unless the filing person has reason to believe such information is not current) beneficially owned (identifying those shares which there is a right to acquire) by each person named in Item 2. The information should also be furnished with respect to persons who, together with any of the persons named in Item 2, comprise a group within the meaning of Section 13(d)(3) of the Act:

    The Reporting Person is the beneficial owner of 12,782,843 shares of Class 2 Common Stock, representing 7.9 % of the outstanding Class 2 Common Stock. The Reporting Person’s ownership includes (1) 9,866,975 shares of Class 2 Common Stock held directly by the Reporting Person, (2) 2,634,053 shares of Class 2 Common Stock that are issuable upon the exercise of options held directly by the Reporting Person that are exercisable within 60 days of February 12, 2021, and (3) 234,940 shares of Class 2 Common Stock held directly by an LLC, of which the Reporting Person is the sole member.

    The percentage in the foregoing paragraph is based on (1) 158,256,763 shares of Class 2 Common Stock that were outstanding as of December 15, 2020, set forth in the Issuer’s Form 8-K filed with the SEC on December 21, 2020, (2) 2,634,053 shares of Class 2 Common Stock that are issuable upon the exercise of options held directly by the Reporting Person that are exercisable within 60 days of February 11, 2021, and (3) 46,875 shares of Class 2 Common Stock that are issuable upon the vesting of restricted stock units held directly by the Reporting Person that will vest within 60 days of December 15, 2020.

     

    3


      (b)

    For each person named in response to paragraph (a), indicate the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition. Provide the applicable information required by Item 2 with respect to each person with whom the power to vote or to direct the vote or to dispose or direct the disposition is shared:

    Regarding the number of shares as to which the Reporting Person has:

     

      a.

    Sole power to vote or to direct the vote: See line 7 of cover sheet.

     

      b.

    Shared power to vote or to direct the vote: See line 8 of cover sheet.

     

      c.

    Sole power to dispose or to direct the disposition: See line 9 of cover sheet.

     

      d.

    Shared power to dispose or to direct the disposition: See line 10 of cover sheet.

     

      (c)

    Describe any transactions in the class of securities reported on that were effected during the past sixty days or since the most recent filing of Schedule 13D (§240.13d-191), whichever is less, by the persons named in response to paragraph (a):

    Information with respect to transactions in the Securities which were effected within the past sixty days or since the most recent filing on Schedule 13D, whichever is less, by the Reporting Person is set forth below.

     

    Date of
    Transaction
             Type of
    Transaction
             Quantity          Class of Stock         

    Price Per Share

    (excluding

    commissions)

    07/31/2020        Cancellation        9,783*        Class 2
    Common Stock
           N/A
    11/04/2020        Sale        400,000        Class 2
    Common Stock
           $6.038**
    11/05/2020        Sale        400,000        Class 2
    Common Stock
           $7.434**
    11/06/2020        Sale        400,000        Class 2
    Common Stock
           $9.883**
    11/10/2020        Option Exercise        380,781        Class 2
    Common Stock
           $7.76
    01/01/2021        RSU Vesting        46,875        Class 2
    Common Stock
           N/A
    01/01/2021        Sale        12,777***        Class 2
    Common Stock
           N/A
    01/25/2021       Cancellation       3,428****      

    Class 2

    Common Stock

          N/A

    * Represents the aggregate number of shares cancelled pursuant to claim against shares held in escrow, including 163 shares held in escrow by an LLC of which the Reporting Person is the sole member.

    **Represents the weighted average sale price.

    ***Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of the RSU.

    **** Represents the aggregate number of shares cancelled pursuant to claim against shares held in escrow, including 57 shares held in escrow by an LLC of which the Reporting Person is the sole member.

     

    4


      (d)

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of an employee benefit plan, pension fund or endowment fund is not required:

    Not applicable.

     

      (e)

    If applicable, state the date on which the reporting person ceased to be the beneficial owner of more than five percent of the class of securities:

    Not applicable.

     

    5


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 16, 2021     By:*    
          Brendan Kennedy

     

    Date: February 16, 2021     *By:   /s/ Julia Stark
          Julia Stark, as Attorney-in-Fact

    This Schedule 13D was executed by Julia Stark on behalf of Brendan Kennedy pursuant to a Power of Attorney, a copy of which was filed the SEC on September 24, 2020.

     

    6

    Get the next $TLRY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLRY

    DatePrice TargetRatingAnalyst
    4/5/2024$2.25 → $2.75Neutral
    Alliance Global Partners
    11/2/2022$3.90Mkt Perform
    Bernstein
    7/29/2022$3.00Hold → Sell
    The Benchmark Company
    3/4/2022$9.00Hold → Buy
    Canaccord Genuity
    1/11/2022$7.40 → $6.90Neutral
    Cantor Fitzgerald
    1/7/2022$11.80 → $7.40Neutral
    Cantor Fitzgerald
    11/18/2021$10.00Underweight
    Barclays
    11/1/2021$18.00 → $11.80Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $TLRY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Shock Top: A Bold Rebrand for a Craft Beer Icon

      PORTLAND, Ore., May 08, 2025 (GLOBE NEWSWIRE) -- Shock Top, a craft beer icon and brand by Tilray Brands, Inc. company (NASDAQ:TLRY, TSX:TLRY), known for its bold flavors and unfiltered wheat ales, today announced a transformative rebrand. With revamped packaging, a new logo, and an expanded, integrated marketing campaign, Shock Top aims to shock a new generation of beer drinkers with a modern look and shocking new seasonal flavors. Building on its legacy of delivering exceptional beers, Shock Top's rebrand introduces a completely new visual identity that enhances its personality and offers a unique experience with every flavor. The new Wedgehead icon is designed as a bolder and more cont

      5/8/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Blue Point Brewing Co. Announces the Return of Delayed Pilsner

      PATCHOGUE, N.Y., May 06, 2025 (GLOBE NEWSWIRE) -- Blue Point Brewing Co., a Tilray Brands, Inc., (NASDAQ:TLRY, TSX:TLRY) craft beer brand, announces the highly anticipated re-release of Delayed Pilsner, a beer crafted to soothe the soul of every New Yorker facing the inevitable delays of city life. Whether it's 2 minutes or 2 hours, delays are scientifically proven to be the bane of any New Yorker's existence. But fear not, Blue Point Brewing has brewed the ultimate lager to get you through this abomination. Delayed Pilsner is brewed with a blend of floral, spicy hops that impart subtle apple and lemon-lime aromas. Balanced by slight honey notes from a creamy malt body, the result is a

      5/6/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • 10 Barrel Brewing Launches Non-Alcoholic Apocalypse IPA, a Bold Craft Brew for Your Next Adventure

      BEND, Ore., April 30, 2025 (GLOBE NEWSWIRE) -- 10 Barrel Brewing, a Tilray Brands, Inc., (NASDAQ:TLRY, TSX:TLRY) craft beer brand, is excited to announce the launch of NA Apocalypse IPA, a non-alcoholic version of their beloved Apocalypse IPA. This new offering delivers the same bold, hop-driven flavor that fans have come to love, now without the alcohol. NA Apocalypse IPA is crafted with the same big flavor to provide the signature punch of pine, citrus, and tropical notes that define the original IPA, minus the alcohol. Whether you're winding down at the end of the day or gearing up for a new adventure, NA Apocalypse IPA offers a taste that's big on hops and light on compromise. "We

      4/30/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Leadership Updates

    Live Leadership Updates

    See more
    • Terrapin Beer Co. Celebrates 20 Years of Iconic Wake-n-Bake Beer with Exciting Wake-n-Bake Off Event in Athens, GA

      ATHENS, Ga., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Terrapin Beer Co., a Tilray Beverages craft beer brand under Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), is excited to announce the 20th anniversary of its Wake-n-Bake Coffee Oatmeal Imperial Stout seasonal beer and the annual Wake-n-Bake Off event on Sunday, January 26th, 2025, at the Terrapin taproom in Athens, GA. In celebration of its 20th anniversary, guests will have the chance to observe local restaurants competing to craft the finest dish featuring Terrapin's renowned Wake-n-Bake Beer. This event highlights culinary innovation and fosters community engagement through an array of sweet and savory tastings that showcase the rich flavor

      1/23/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Blue Point Brewing Launches Big Mo Brew to Raise Funds and Awareness for Men's Health During Movember

      PATCHOGUE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Blue Point Brewing Company, Long Island's original craft brewery and subsidiary of Tilray Brands, (NASDAQ:TLRY, TSX:TLRY), is proud to announce the continuation of its men's health awareness campaign in support of Movember. The month shines a light on key men's health issues—mental health, prostate cancer, and testicular cancer—encouraging open conversations and proactive engagement. To honor the initiative, Blue Point Brewing announced the special release of its classic double IPA, Big Mo, available at our brewery and retailers in Long Island, New York. This hazy double IPA, featuring prominent mosaic hops and an ABV of 8.0%, proud

      10/22/24 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Breckenridge Brewery Opens New Location in Fort Collins, Colorado

      FORT COLLINS, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery, a Colorado-based craft brewer with over 30 years of experience brewing approachable, well-balanced beers, announces the opening of its new brewery location in Fort Collins. With doors opening in early August 2024, the new 10,000-square-foot Breckenridge Brewery offers a full restaurant experience and a new vibrant atmosphere in the heart of Fort Collins for all to enjoy. The new location will be a full-service restaurant, upholding the Breckenridge Brewery legacy while ushering in new opportunities for innovation and community collaboration. With a menu boasting a diverse range of culinary delights designed to co

      8/5/24 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Financials

    Live finance-specific insights

    See more
    • Tilray Brands Reports Q3 Fiscal 2025 Financial Results

      Tilray Confirms No Current Impact of Tariffs Generated Net Revenue of $186 Million in the Third Quarter, $193 Million in Constant Currency; Strategic Initiatives and SKU Rationalization Impacted Revenue by $13 Million Tilray Beverage Expands U.S. Distribution of Hemp-Derived THC Drinks Across 10 States, Increases Project 420 Cost Savings Plan to $33 Million Tilray Cannabis Increased Gross Margins by 800 bps, Remains the Leader in Canada by Sales Performance, and Generates Strong Sales Growth in Germany Strengthens Balance Sheet with Convertible Note Reduction of $58 Million and Total Debt Reduction of $71 Million, $248 Million Available in Cash and Marketable Securities NEW Y

      4/8/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands, Inc. to Announce Third Quarter Fiscal 2025 Financial Results on April 8, 2025

      NEW YORK and LEAMINGTON, Ontario, March 27, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis and wellness industries, today announced that the Company will release financial results for its third quarter fiscal 2025 ended February 28, 2025 before financial markets open on April 8, 2025. Live Conference Call and Audio Webcast Tilray will hold a live conference call, which will be webcast, to discuss these results at 8:30 a.m. Eastern Time. The webcast can be accessed in the Investors section of Tilray's website at www.Tilray.com. About Tilray Bran

      3/27/25 4:30:00 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands Reports Q2 2025 Financial Results

      Gross Profit Increased by 29% Year-Over-Year, Reaching $61 Million in Q2 with Growth Across All Four Business Segments Achieved 9% Year-Over-Year Growth, Generating Record Q2 Net Revenue of $211 Million, 10% in Constant Currency Beverage Revenue Increase by 36%, International Cannabis by 25%, Wellness Segment by 13% Announces Project 420: A $25 Million Synergy Plan for Tilray Beverage Business Tilray Reaffirms Fiscal Year 2025 Guidance Conference Call to be Held at 8:30 a.m. ET Today NEW YORK and LEAMINGTON, Ontario, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray", "our", "we" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods co

      1/10/25 7:00:50 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Tilray Brands Inc.

      DEFA14A - Tilray Brands, Inc. (0001731348) (Filer)

      4/28/25 4:55:34 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Tilray Brands Inc.

      DEF 14A - Tilray Brands, Inc. (0001731348) (Filer)

      4/28/25 4:53:44 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

      8-K - Tilray Brands, Inc. (0001731348) (Filer)

      4/25/25 4:06:00 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Merton Carl A bought $35,360 worth of shares (26,000 units at $1.36) (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      11/18/24 11:29:05 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Faltischek Denise M bought $20,500 worth of shares (10,000 units at $2.05), increasing direct ownership by 4% to 293,269 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      1/18/24 8:32:10 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Gendel Mitchell bought $14,256 worth of shares (7,200 units at $1.98), increasing direct ownership by 4% to 195,796 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      1/16/24 1:07:47 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Tilray Brands Inc. (Amendment)

      SC 13G/A - Tilray Brands, Inc. (0001731348) (Subject)

      2/13/23 1:34:44 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Tilray Brands Inc.

      SC 13G - Tilray Brands, Inc. (0001731348) (Subject)

      2/10/23 4:41:36 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Tilray Brands Inc.

      SC 13D - Tilray Brands, Inc. (0001731348) (Filed by)

      7/22/22 4:30:22 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Cohen Steven Michael

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      1/8/25 4:16:07 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • New insider Cohen Steven Michael claimed no ownership of stock in the company (SEC Form 3)

      3 - Tilray Brands, Inc. (0001731348) (Issuer)

      12/17/24 4:05:56 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Merton Carl A bought $35,360 worth of shares (26,000 units at $1.36) (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      11/18/24 11:29:05 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners reiterated coverage on Tilray with a new price target

      Alliance Global Partners reiterated coverage of Tilray with a rating of Neutral and set a new price target of $2.75 from $2.25 previously

      4/5/24 7:39:50 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bernstein initiated coverage on Tilray with a new price target

      Bernstein initiated coverage of Tilray with a rating of Mkt Perform and set a new price target of $3.90

      11/2/22 6:37:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray downgraded by The Benchmark Company with a new price target

      The Benchmark Company downgraded Tilray from Hold to Sell and set a new price target of $3.00

      7/29/22 7:19:40 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care